{"entity":{"id":"balstilimab","kind":"drug","name":"Balstilimab","aka":["AGEN2034"],"tldr":"Balstilimab is a monoclonal antibody from Agenus Inc., in registered phase 2 trials for colorectal cancer.","summary":"Balstilimab is listed on ClinicalTrials.gov as an intervention in 1 registered phase 2 trial sponsored by Agenus Inc. and ImmunoGenesis, in colorectal cancer. A monoclonal antibody: the international non-proprietary name stem -mab marks an antibody that binds one target. The registry record does not state the target unless named in the trial entries below. OnCo records the agent from the registry alone; approvals, results and the sponsor's own description will follow as they are published.","status":"phase-2","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov: trials of Balstilimab","url":"https://clinicaltrials.gov/search?intr=Balstilimab"}],"tags":["pipeline","ctgov-ingest","registry-only"],"related":[],"cancers":["colorectal"],"sections":[],"technologies":[],"targets":["pd1"],"drugs":[],"companies":["agenus"],"institutions":[],"pathways":[],"terms":[],"trials":["nct05608044","nct05205330","nct06782555"],"people":[],"bottlenecks":[],"keyPapers":["paper-bullock-botensilimab-balstilimab-mss-colorectal-nat-med-2024"],"journals":[],"dependsOn":[],"notes":["Colorectal cancer: the anti-PD-1 half of the botensilimab pairing tested in 148 heavily pre-treated microsatellite-stable patients, where the combination gave a 17% objective response rate and 61% disease control (Bullock 2024)."],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2, registry-only)","editedOn":"2026-09-16"},"modality":"Monoclonal antibody","mechanism":"A monoclonal antibody: the international non-proprietary name stem -mab marks an antibody that binds one target. The registry record does not state the target unless named in the trial entries below.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/balstilimab/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"}],"target":[{"id":"pd1","kind":"target","name":"PD-1","route":"/targets/pd1/"}],"company":[{"id":"agenus","kind":"company","name":"Agenus","route":"/companies/agenus/"}],"trial":[{"id":"nct07227636","kind":"trial","name":"A Study of Botensilimab and Balstilimab for Colorectal Cancer With ctDNA+ After Surgery and Chemotherapy","route":"/trials/nct07227636/"},{"id":"nct06843434","kind":"trial","name":"A Study of Botensilimab and Balstilimab for Rectal Adenocarcinoma","route":"/trials/nct06843434/"},{"id":"nct05608044","kind":"trial","name":"A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer","route":"/trials/nct05608044/"},{"id":"nct06782555","kind":"trial","name":"A Study of Evofosfamide in Combination with Zalifrelimab and Balstilimab","route":"/trials/nct06782555/"},{"id":"nct07550088","kind":"trial","name":"BAL/BOT/agenT-797 in pMMR CRC With Liver Metastases","route":"/trials/nct07550088/"},{"id":"nct06782932","kind":"trial","name":"Comparing Neoadjuvant/Adjuvant GVAX vs a mKRASvax Given With Anti-PD-1 and Anti-CD137 for Surgically Resectable Pancreatic Cancer","route":"/trials/nct06782932/"},{"id":"nct06780787","kind":"trial","name":"FOLFOX, Botensilimab, and Balstilimab for the Treatment of Localized Rectal Cancer Before Surgery","route":"/trials/nct06780787/"},{"id":"nct05318469","kind":"trial","name":"Ivermectin with balstilimab or pembrolizumab in metastatic triple-negative breast cancer (Cedars-Sinai phase 1/2)","route":"/trials/nct05318469/"},{"id":"nct07595874","kind":"trial","name":"Neoadjuvant Botensilimab and Balstilimab for the Treatment of Advanced Resectable Colorectal Cancer NEST3","route":"/trials/nct07595874/"},{"id":"nct05864534","kind":"trial","name":"Phase 2a Immune Modulation With Ultrasound for Newly Diagnosed Glioblastoma","route":"/trials/nct05864534/"},{"id":"nct06300463","kind":"trial","name":"Platform Study of Immunotherapy Combinations in Colorectal Cancer Liver Metastases","route":"/trials/nct06300463/"},{"id":"nct05845450","kind":"trial","name":"Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)","route":"/trials/nct05845450/"},{"id":"nct07735624","kind":"trial","name":"RECTIFY-1: Neoadjuvant Botensilimab + Balstilimab in MSS/pMMR Early Rectal Cancer","route":"/trials/nct07735624/"},{"id":"nct07551596","kind":"trial","name":"Testing the Combination of Anti-Cancer Drugs, Botensilimab (AGEN1181) and Balstilimab (AGEN2034), After Standard Treatment for Colorectal Cancer, Combat Trial","route":"/trials/nct07551596/"},{"id":"nct06843551","kind":"trial","name":"The Miami \"EMPIRE\" Trial - Eradication of Metastatic Pancreatic Cancer With Immuno-Radiation","route":"/trials/nct06843551/"},{"id":"nct05205330","kind":"trial","name":"Vorbipiprant (CR6086) / Balstilimab (AGEN2034) Combination in Stage IV Refractory pMMR - MSS CRC, and Other Metastatic GI Cancers","route":"/trials/nct05205330/"}],"paper":[{"id":"paper-bullock-botensilimab-balstilimab-mss-colorectal-nat-med-2024","kind":"paper","name":"Botensilimab plus balstilimab in relapsed/refractory microsatellite stable metastatic colorectal cancer: a phase 1 trial","route":"/key-papers/paper-bullock-botensilimab-balstilimab-mss-colorectal-nat-med-2024/"}],"idea":[{"id":"idea-crc-mss-immunotherapy-by-biomarker-not-by-line","kind":"idea","name":"Select microsatellite stable patients for immunotherapy by a measured immune biomarker, not by how many treatments they have already failed","route":"/ideas/idea-crc-mss-immunotherapy-by-biomarker-not-by-line/"}],"drug":[{"id":"ivermectin","kind":"drug","name":"Ivermectin","route":"/drugs/ivermectin/"}]}}